Hemab ApS
Hemab Therapeutics is a clinical-stage biotech company dedicated to developing innovative prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, the company is building a pipeline of monoclonal and bispecific antibody-based solutions to transform treatment paradigms for high unmet need blood-clotting disorders such as Glanzmann thrombasthenia, Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, and others. Their strategic guidance, Hemab 1-2-5TM, aims to develop five clinical assets by 2025 to deliver long-awaited medical innovations, including the promising candidate HMB-001, a bispecific antibody designed to stabilize and recruit endogenous factor VIIa for prophylactic treatment.
Industries
Nr. of Employees
small (1-50)
Products
HMB-001
A bispecific antibody designed for prophylactic treatment of Glanzmann Thrombasthenia and Factor VII Deficiency by binding, stabilizing, and recruiting endogenous factor VIIa to the site of vascular injury.
HMB-002
Designed as a prophylactic treatment for Von Willebrand Disease Type 1 and 2.
HMB-001
A bispecific antibody designed for prophylactic treatment of Glanzmann Thrombasthenia and Factor VII Deficiency by binding, stabilizing, and recruiting endogenous factor VIIa to the site of vascular injury.
HMB-002
Designed as a prophylactic treatment for Von Willebrand Disease Type 1 and 2.
News & Updates
Hemab will present 11 abstracts at the ISTH 2025 Congress, including interim results from Phase 2 studies of HMB-001 and early data on HMB-002, highlighting their pipeline of therapeutics for bleeding disorders.
The first participant with Von Willebrand Disease has been dosed in the Velora Pioneer trial, evaluating HMB-002, a subcutaneous therapy aimed at increasing endogenous VWF and FVIII levels.
Initial results from Phase 1 of HMB-001 show it was well tolerated with dose-dependent improvements in blood-clotting activity, supporting its potential as a prophylactic treatment.
Preclinical data demonstrate HMB-001's ability to target and accumulate endogenous FVIIa, supporting its potential in treating FVII deficiency and Glanzmann Thrombasthenia.
The Phase 1/2 study of HMB-001 has transitioned to the multiple-ascending dose phase, with the U.S. FDA having cleared the IND and granted Fast Track designation.
Dr. Vaishnaw, Chief Innovation Officer at Alnylam, joins Hemab's board as the company advances multiple clinical programs for bleeding disorders.
Hemab will present 11 abstracts at the ISTH 2025 Congress, including interim results from Phase 2 studies of HMB-001 and early data on HMB-002, highlighting their pipeline of therapeutics for bleeding disorders.
The first participant with Von Willebrand Disease has been dosed in the Velora Pioneer trial, evaluating HMB-002, a subcutaneous therapy aimed at increasing endogenous VWF and FVIII levels.
Initial results from Phase 1 of HMB-001 show it was well tolerated with dose-dependent improvements in blood-clotting activity, supporting its potential as a prophylactic treatment.
Preclinical data demonstrate HMB-001's ability to target and accumulate endogenous FVIIa, supporting its potential in treating FVII deficiency and Glanzmann Thrombasthenia.
The Phase 1/2 study of HMB-001 has transitioned to the multiple-ascending dose phase, with the U.S. FDA having cleared the IND and granted Fast Track designation.
Dr. Vaishnaw, Chief Innovation Officer at Alnylam, joins Hemab's board as the company advances multiple clinical programs for bleeding disorders.